VCAN and neoplasm: Ligands for FFAR2 (G protein-coupled receptor 43, GPR43) inhibit the TNF-α signaling pathway [84], thus FFAR2 − TNF being upregulated signifies the suppressive effect of VCAN+ TAMs on anti-tumor immunity.